Histone acetylation at the Ifng promoter in tolerized CD4 cells is associated with increased IFN-γ expression during subsequent immunization to the same antigen

Journal of Immunology

Volumn 179, Issue 9, 2007, Pages 5669-5677

  Long, Meixiao ^a   Slaiby, Aaron M ^a   Wu, Shuang ^a   Hagymasi, Adam T ^a   Mihalyo, Marianne A ^a   Bandyopadhyay, Suman ^a   Vella, Anthony T ^a   Adler, Adam J ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CYTOKINE; EPITOPE; GAMMA INTERFERON; HISTONE; T LYMPHOCYTE RECEPTOR; ANTIGEN;

ACETYLATION; ADOPTIVE TRANSFER; ANIMAL CELL; ANTIGENICITY; ARTICLE; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CONTROLLED STUDY; DNA MODIFICATION; DOSE RESPONSE; EPIGENETICS; GENE; GENETIC TRANSCRIPTION; IFNG GENE; IMMUNIZATION; IMMUNOSTIMULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; SIGNAL TRANSDUCTION; TRANSGENICS; ANIMAL; ANTIGEN PRESENTING CELL; GENETICS; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; METABOLISM; SPLEEN; TRANSGENIC MOUSE;

ACETYLATION; ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS; CD4-POSITIVE T-LYMPHOCYTES; HISTONES; IMMUNE TOLERANCE; IMMUNIZATION; INTERFERON TYPE II; MICE; MICE, TRANSGENIC; PROMOTER REGIONS (GENETICS); SPLEEN;

EID: 38449113713     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.179.9.5669     Document Type: Article

References (42)

1. Murphy, K. M., and S. L. Reiner. 2002. Decision making in the immune system: The lineage decisions of helper T cells. Nat. Rev. Immunol. 2: 933-944.
2. Glimcher, L. H., M. J. Townsend, B. M. Sullivan, and G. M. Lord. 2004. Recent developments in the transcriptional regulation of cytolytic effector cells. Nat. Rev. Immunol. 4: 900-911.
3. Weaver, C. T., L. E. Harrington, P. R. Mangan, M. Gavrieli, and K. M. Murphy. 2006. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 24: 677-688.
4. Pulendran, B. 2005. Variegation of the immune response with dendritic cells and pathogen recognition receptors. J. Immunol. 174: 2457-2465.
5. Agarwal, S., and A. Rao. 1998. Modulation of chromatin structure regulates cytokine gene expression during T cell differentiation. Immunity 9: 765-775.
6. Bird, J. J., D. R. Brown, A. C. Mullen, N. H. Moskowitz, M. A. Mahowald, J. R. Sider, T. F. Gajewski, C. R. Wang, and S. L. Reiner. 1998. Helper T cell differentiation is controlled by the cell cycle. Immunity 9: 229-237.
7. Avni, O., D. Lee, F. Macian, S. J. Szabo, L. H. Glimcher, and A. Rao. 2002. TH cell differentiation is accompanied by dynamic changes in histone acetylation of cytokine genes. Nat. Immunol. 3: 643-651.
8. Janeway, C. A., Jr. 1989. Approaching the asymptote? evolution and revolution in immunology. Cold Spring Harb. Symp. Quant. Biol. 54: 1-13.
9. Matzinger, P. 1994. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12: 991-1045.
10. Jenkins, M. K., A. Khoruts, E. Ingulli, D. L. Mueller, S. J. McSorley, R. L. Reinhardt, A. Itano, and K. A. Pape. 2001. In vivo activation of antigen-specific CD4 T cells. Annu. Rev. Immunol. 19: 23-45.
11. Steinman, R. M., and M. C. Nussenzweig. 2002. Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc. Natl. Acad. Sci. USA 99: 351-358.
12. + T cell tolerance induction versus priming is independent of the rate and number of cell divisions. J. Immunol. 164: 649-655.
13. Higgins, A. D., M. A. Mihalyo, P. W. McGary, and A. J. Adler. 2002. CD4 cell priming and tolerization are differentially programmed by APCs upon initial engagement. J. Immunol. 168: 5573-5581.
14. + T cells pass through an effector phase during the process of in vivo tolerance Induction. J. Immunol. 170: 3945-3953.
15. Zhou, G., Z. Lu, J. D. McCadden, H. I. Levitsky, and A. L. Marson. 2004. Reciprocal Changes in tumor antigenicity and antigen-specific T cell function during tumor progression. J. Exp. Med. 200: 1581-1592.
16. Szabo, S. J., S. T. Kim, G. L. Costa, X. Zhang, C. G. Fathman, and L. H. Glimcher. 2000. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 100: 655-669.
17. Mullen, A. C., F. A. High, A. S. Hutchins, H. W. Lee, A. V. Villarino, D. M. Livingston, A. L. Kung, N. Cereb, T. P. Yao, S. Y. Yang, and S. L. Reiner. 2001. Role of T-bet in commitment of TH1 cells before IL-12-dependent selection. Science 292: 1907-1910.
18. Ramsdell, F., and B. J. Fowlkes. 1992. Maintenance of in vivo tolerance by persistence of antigen. Science 257: 1130-1134.
19. + T cells persist in vivo following induction of peripheral tolerance. J. Immunol. 160: 4719-4729.
20. Drake, C. G., A. D. Doody, M. A. Mihalyo, C. T. Huang, E. Kelleher, S. Ravi, E. L. Hipkiss, D. B. Flies, E. P. Kennedy, M. Long, et al. 2005. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell 7: 239-249.
21. Adler, A. J. 2007. Mechanisms of T cell tolerance and suppression in cancer mediated by tumor-associated antigens and hormones. Curr. Cancer Drug Targets 7: 3-14.
22. + single positive cells with a class II major histocompatibility complex-restricted receptor. J. Exp. Med. 180: 25-34.
23. + T cell tolerance to parenchymal self-antigens requires presentation by bone marrow-derived antigen presenting cells. J. Exp. Med. 187: 1555-1564.
24. Grubin, C. E., S. Kovats, P. deRoos, and A. Y. Rudensky. 1997. Deficient positive selection of CD4 T cells in mice displaying altered repertoires of MHC class II-bound self-peptides. Immunity 7: 197-208.
25. Higgins, A. D., M. A. Mihalyo, and A. J. Adler. 2002. Effector CD4 cells are tolerized upon exposure to parenchymal self-antigen. J. Immunol. 169: 3622-3629.
26. Long, M., A. D. Higgins, M. A. Mihalyo, and A. J. Adler. 2003. Effector CD4 cell tolerization is mediated through functional inactivation and involves preferential impairment of TNF-α and IFN-γ expression potentials. Cell Immunol. 224: 114-121.
27. Long, M., A. M. Slaiby, A. T. Hagymasi, M. A. Mihalyo, A. C. Lichtler, S. L. Reiner, and A. J. Adler. 2006. T-bet down-modulation in tolerized Th1 effector CD4 cells confers a TCR-distal signaling defect that selectively impairs IFN-γ expression. J. Immunol. 176: 1036-1045.
28. Fields, P. E., S. T. Kim, and R. A. Flavell. 2002. Cutting edge: changes in histone acetylation at the IL-4 and IFN-γ loci accompany Th1/Th2 differentiation. J. Immunol. 169: 647-650.
29. + T lymphocytes into effector CTL. J. Immunol. 172: 6558-6567.
30. + T cell lineage commitment. Nat. Immunol. 6: 793-799.
31. + T cell survival controlled by clonal abundance. Science 312: 114-116.
32. + T cells. Nat. Immunol. 3: 549-557.
33. Ohashi, P. S. 2002. T-cell signalling and autoimmunity: molecular mechanisms of disease. Nat. Rev. Immunol. 2: 427-438.
34. Adler, A. J. 2005. Peripheral tolerization of effector and memory T cells: implications for autoimmunity and tumor-immunity. Curr Immunol. Rev. 1: 21-28.
35. + T cell effector function. J. Immunol. 172: 6087-6092.
36. Schwartz, R. H. 2003. T cell anergy. Annu. Rev. Immunol. 21: 305-334.
37. Mueller, D. L. 2004. E3 ubiquitin ligases as T cell anergy factors. Nat. Immunol. 5: 883-890.
38. Stavely-O'Carroll, K., E. Sotomayor, J. Montgomery, I. Borrello, L. Hwang, S. Fein, D. Pardoll, and H. Levitsky. 1998. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc. Natl. Acad. Sci. USA 95: 1178-1183.
39. + T cells in the antitumor immune response. J. Exp. Med. 188: 2357-2368.
40. + T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity 12: 677-686.
41. Ikeda, H., L. J. Old, and R. D. Schreiber. 2002. The roles of IFN γ in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev. 13: 95-109.
42. Winter, H., H. M. Hu, K. McClain, W. J. Urba, and B. A. Fox. 2001. Immunotherapy of melanoma: a dichotomy in the requirement for IFN-gamma in vaccine-induced antitumor immunity versus adoptive immunotherapy. J. Immunol. 166: 7370-7380.